Phase 3 trial of pamrevlumab for idiopathic pulmonary fibrosis did not significantly improve lung function compared to placebo.
A phase 3 clinical trial for idiopathic pulmonary fibrosis (IPF) patients found that pamrevlumab, an inhibitor of connective tissue growth factor, did not significantly improve forced vital capacity change from baseline to week 48 compared to placebo. IPF treatments currently only slow lung function decline and have side effects affecting medication adherence. The trial's success lies in patient adherence despite pandemic challenges, and the findings will help inform future IPF treatment trials.
May 19, 2024
3 Articles